MAIA Biotechnology, Inc.
MAIA Biotechnology, Inc. (NYSE American: MAIA) is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer treatment. The company's website is www.MAIABiotech.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What MAIA Biotechnology, Inc. does
In the company’s own words
MAIA Biotechnology, Inc. (NYSE American: MAIA) is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer treatment. The company's website is www.MAIABiotech.com.
The company's lead asset is ateganosine, an investigational dual mechanism of action drug candidate that incorporates telomere targeting and immunogenicity. Ateganosine works by targeting telomeres, the repetitive DNA sequences at chromosome ends that play a fundamental role in cancer cell survival and resistance to current therapies. The drug's mechanism involves telomerase recognition of ateganosine's metabolite, which becomes incorporated into cancer cell telomeres, creating faulty structures that break apart and trigger cancer cell death. The company believes ateganosine transforms immunologically "cold" tumors into "hot" tumors responsive to immunotherapy, a process occurring within 24 to 72 hours.
MAIA is advancing ateganosine through multiple clinical programs. The Phase 2 THIO-101 trial evaluates ateganosine in sequential combination with checkpoint inhibitors for non-small cell lung cancer patients. In 2025, the company initiated the Phase 3 THIO-104 pivotal trial comparing ateganosine sequenced with checkpoint inhibitors to chemotherapy in third-line NSCLC patients. Additional Phase 2 trials are planned for hepatocellular carcinoma, colorectal cancer, and small cell lung cancer in combination with checkpoint inhibitors.
The company has established strategic collaborations with major pharmaceutical partners including Regeneron for cemiplimab supply, BeOne Medicines for tislelizumab, and Roche for atezolizumab. MAIA has received multiple regulatory designations including orphan drug designations for hepatocellular carcinoma, small cell lung cancer, and malignant gliomas, as well as rare pediatric disease designation and fast track designation for NSCLC treatment.
MAIA maintains operations in Chicago, Illinois, with a wholly-owned Australian subsidiary established in 2021 and a Romanian subsidiary established in 2022. The company is developing a pipeline of second-generation telomere-targeting compounds, with seven molecules selected for further evaluation in preclinical and in vivo models. The company's intellectual property portfolio comprises ten issued patents worldwide and twenty-four pending patent applications covering telomere-targeting compounds and combination treatment strategies.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- CHICAGO, IL
- Fiscal year end
- December
- CIK
- 1878313
- SIC
- 2834
Financial performance, year by year
Fiscal 2022–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns MAIA Biotechnology, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · MAIA Biotechnology, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do MAIA Biotechnology, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of MAIA Biotechnology, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in MAIA Biotechnology, Inc.'s last four quarterly filings that the numbers alone won't show?”